On Tuesday, the U.S. Food and Drug Administration (FDA) approved Novo Nordisk A/S' (NYSE:NVO) Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.

Wegovy pill became the first oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management.

The approval was based on the OASIS trial program and the SELECT trial.

Also Read: Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Data

In the OASIS 4 trial, oral semaglutide 25 mg taken once daily demonstrated 16.6% mean weight loss when treatment was adhered to in adult participants with obesity or overweight with one or more comorbidities.

The weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg.

Furthermore, one in three people experienced 20% or greater weight loss in the OASIS 4 trial.

Novo Nordisk expects to launch the Wegovy pill in the ...